DocWire News Editors

DocwireNews

At the annual meeting, a group of researchers led by Iain B. McInnes, MBChB, MRCP, PhD, of the University of Glasgow in the United Kingdom, presented long-term data from a phase III study evaluating the safety and efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA). The study concluded that SEC led to sustained improvement in the signs and symptoms of PsA over four years, and patients tolerated the treatment well. In addition, the treatment&rsquo;s effectiveness was sustained or further improved after dose escalation.The FUTURE 2 study has been examining SEC, a fully human monoclonal IgG1 antibody that selectively neutralizes interleukin-17A. The study randomized 397 patients with active PsA to receive either SEC (300 mg, 150 mg, or 75 mg) or placebo every week, then every four weeks starting at week eight.Starting at week 128, patients with active signs of disease received dose escalation (from 150 mg to 300 mg, or from 75 mg to 150 mg or 300 mg), which continued thereafter. At week 208, researchers performed assessments, including the American College of Rheumatology 20/50/70 Criteria, the Psoriasis Area and Severity Index 75/90, the Health Assessment Questionnaire Disability Index, and the 36-Item Short Form Health Survey Physical Component Summary; they also assessed whether resolution of dactylitis and enthesitis occurred.Overall, 69 of 100 (69%) patients originally randomized to receive SEC 300 mg, 70 of 100 patients (70%) originally randomized to receive SEC 150 mg, and 62 of 99 patients (63%) originally randomized to receive SEC 75 mg completed 208 weeks of treatment. Subsequently, 46 of 100 patients (46%) in the 150 mg group were escalated to 300 mg, and 56 of 99 patients (57%) in the 75 mg group were escalated to 150 or 300 mg.Researchers found that clinical responses were sustained through week 208 with 300 mg, and responses were sustained or further improved following dose escalation. Safety, type, incidence, and severity of adverse events (AEs) were consistent with previous reports from the FUTURE 2 study.&nbsp;Three patients experienced treatment-emergent anti-drug antibodies, but there was no neutralizing antibody or loss of efficacy. Only one death was reported in four years in a patient in the 150 mg, which was due to sepsis.The researchers concluded that SEC 300 mg or 150 mg provided efficacy over four years against the signs and symptoms of PsA and that dose escalation sustained or improved the effects. The researchers also reported that the treatment was well tolerated, with no new or unexpected AEs.

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Research Shows Secukinumab Is Effective in the Long Term Against Signs and Symptoms of Active Psoriatic Arthritis

ACR 2018 Conference

At the annual meeting, a group of researchers led by Iain B. McInnes, MBChB, MRCP, PhD, of the University of Glasgow in the United Kingdom, presented long-term data from a ...

Research Shows Secukinumab Is Effective in the Long Term Against Signs and Symptoms of Active

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe